CpG or IFN-α Are More Potent Adjuvants Than GM-CSF to Promote Anti-Tumor Immunity Following Idiotype Vaccine in Multiple Myeloma

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-011-1123-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Anti‐GM‐CSF Therapy in Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Skin Substitutes Are More Potent Than Dermal or Epidermal Substitutes in Stimulating Endothelial Cell Sprouting

BMC Biomedical Engineering
2019English

Hypodiploid Multiple Myeloma Is Characterized by More Aggressive Molecular Markers Than Non-Hyperdiploid Multiple Myeloma

Haematologica
Hematology
2013English

Immunostimulatory Oligodeoxynucleotides Containing the CpG Motif Are Effective as Immune Adjuvants in Tumor Antigen Immunization

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1997English

PPAR-γ Contributes to Immunity by Cancer Vaccines That Secrete GM-CSF

Cancer immunology research
Cancer ResearchImmunology
2018English

Toll-Like Receptor 9 (TLR9) or TLR3 Adjuvants to Promote Cancer Vaccine–induced Effector T Cell Expansion

Science-Business eXchange
2013English

Comparison of Peripheral Blood Progenitor Cell Mobilization in Patients With Multiple Myeloma: High-Dose Cyclophosphamide Plus GM-CSF vs G-CSF Alone

Bone Marrow Transplantation
TransplantationHematology
1997English

Methyl-CpG Binding Proteins and Cancer: Are MeCpGs More Important Than MBDs?

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Innate and Adaptive Immunity Contribute to the Anti-Tumor Mechanisms of Action of OncoVEXmGM-CSF

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy